Major inflection point.

What does it mean that the CMS decision to cover CAR-T cell therapy for all FDA-approved indications? For both Yescarta and Kymriah, that includes relapsed/refractory large B-cell lymphomas after two lines of therapy. Kymriah is also approved for refractory B-cell precursor ALL in patients under 25. | CMS 2019